Lundbeck preps for war against generic drugmakers in US

Lundbeck is facing a patent dispute concerning its second-best selling drug, schizophrenia treatment Rexulti, against companies wanting to reproduce generic versions. CEO Deborah Dunsire will sound the charge this summer.
Photo: Lundbeck / PR
Photo: Lundbeck / PR
by BENJAMIN WERNER CHRISTENSEN, translated by daniel pedersen

Pharmaceutical firm Lundbeck is arming itself for battle with several generic drugmakers wanting to produce generic versions of schizophrenia treatment Rexulti before its patent expires.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading